BioCentury

7:00 AM GMT, Jun 14, 2010
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical Results

Tivozanib: Additional Phase II data

Additional data from a placebo-controlled Phase II trial in 272 patients naïve to VEGF therapy showed that once-daily oral tivozanib led to a median

Read the full 244 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.